tiprankstipranks
Trending News
More News >

Abeona Therapeutics price target raised to $20 from $15 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Abeona Therapeutics (ABEO) to $20 from $15 and keeps a Buy rating on the shares after the FDA approved the biologics license application for the company’s lead candidate, prademagene zamikeracel. The approval is on schedule with much higher than projected pricing and solid commercial plan, the analyst tells investors in a research note.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue